Hide

Immunisation Weekly Update:

20190319 Immunisation Needle Icons 31
  • Ensure your eligible patients are vaccinated against Mpox
  • NCIRS 2023 immunisation coverage report is now available
  • 3G network closure: check your wireless data logger
  • New COVID resources for RACHs
  • Education

NSW is now seeing the largest mpox outbreak in the state since the first case was confirmed in May 2022. Currently, people at most risk of mpox in NSW are men who have sex with men, sex workers and their sexual partners.

Vaccination is a critical step in reducing the spread of the virus to protect people who are most at risk. It is a safe and effective way to protect against severe illness from mpox.

Two doses of mpox vaccine are required 28 days apart to combat serious illness. Vaccination is free for eligible populations (no Medicare care required). A list of mpox vaccination clinics is available here.

Resources

  • NSW Health have released a Mpox awareness toolkit, which includes information and resources, including translated resources for multicultural groups.
  • Health providers are encouraged to download and print this poster to place in waiting rooms to assist in spreading awareness.
  • There is also a fact sheet available outlining information about mpox symptoms, risks and treatment.

S100 prescribers can administer mpox vaccination

 To assist in access to mpox vaccination, all s100 prescribers are invited to receive NSW Health funded Jynneos vaccine for their eligible patients. If you would like to receive Jynneos vaccine please contact your local public health unit on 1300 066 055.

Further information available on our mpox webpage.

NCIRS’ latest annual immunisation coverage report has revealed vaccination coverage rates among children in Australia have declined for the third consecutive year.

The report shows that in 2023, fully vaccinated coverage rates for children overall decreased at all three standard age assessment milestones: 12 months (to 92.8%, from 93.3% in 2022 and 94.8% in 2020), 24 months (to 90.8%, from 91.0% in 2022 and 92.1% in 2020) and 60 months (to 93.3%, from 93.4% in 2022 and 94.8% in 2020). 

Register your practice to participate in our Immunisation QI Activity: AIR Overdue Childhood Immunisations.

CESPHN can support practices in implementing various Immunisation QI activities, with straightforward and practical guidance from our Immunisation Officers. Contact immunisation@cesphn.com.au

With the closure of the 3G network on Monday 28 October, it is recommended providers check their wireless data loggers are connected and continuously monitoring.

Those with Medisafe vaccine specific fridges that use AQ Box for data logging can contact the Medisafe team for further support.

REGISTER 6 November 2024 7:00pm – 8:30pm AEDSTRSV and Mothers-to-Be This session will delve into the significant burden of RSV on infants and explore preventive strategies, including practical guidance on integrating RSV vaccination into routine antenatal care.
REGISTER 7 November 2024 6:00pm – 7:00pm AEDSTNSW RSV prevention program 2025 This NSW Health webinar will outline the disease impact of RSV on infants, vaccine efficacy of the maternal vaccination product Abrysvo, the RSV prevention program in NSW and ACT, and practical tips on vaccination for midwives. The webinar is for all clinicians involved in providing care to pregnant women in the antenatal and postnatal periods and caring for newborn infants and children with medical risk conditions for severe RSV disease.
REGISTER 21 November 2024 7:00pm – 8:00pm AEDSTNational Mpox Webinar: Vaccination and Testing There has been an increase of local mpox transmission rates in Australia, namely in NSW and VIC, but also in most jurisdictions. Although vaccination rates are rising, in NSW and VIC, only 15-20% have completed the full required course of two doses of the mpox vaccine (GBQ+ periodic survey). This webinar is for doctors & nurses in all healthcare settings and will discuss vaccination strategies, when to consider mpox as a differential diagnosis, and provide insights on clade 1b.